查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869846

胜肽和寡核苷酸CDMO市場規模、佔有率和趨勢分析報告：按產品、服務、最終用途、地區和預測（2025-2033年）分類的細分市場預測

Peptide And Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Product (Peptides, Oligonucleotides) By Service (Contract Development, Contract Manufacturing), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

胜肽和寡核苷酸CDMO市場摘要

預計到 2024 年，全球胜肽和寡核苷酸 CDMO 市場規模將達到 28 億美元，到 2033 年將達到 81.4 億美元。

預計從 2025 年到 2033 年，該產業將以 12.75% 的複合年成長率成長。成長要素包括對複雜靶向療法的需求不斷成長、對生物製藥和核酸藥物開發的投資不斷增加、製藥和生物製藥公司外包趨勢的上升，以及胜肽和寡核苷酸合成和遞送技術的進步。

此外，寡核苷酸和胜肽在治療多種疾病方面展現出巨大潛力，包括代謝紊亂、癌症和遺傳性疾病。胜肽合成、合成化學和寡核苷酸生產技術的創新使得複雜分子的生產和設計更加便利。這顯著拓展了胜肽和寡核苷酸在治療領域的應用，從而推動了對具備相關領域專業知識的合約研發生產機構（CDMO）的需求。

此外，個人化醫療的日益普及推動了對客製化胜肽和寡核苷酸療法的需求，進而帶動了合約研發生產機構（CDMO）的需求，這些機構在這些個人化療法的生產和開發中發揮關鍵作用。同時，歐洲藥品管理局（EMA）和美國食品藥物管理局（FDA）等監管機構也積極制定寡核苷酸和胜肽的生產和開發指南。因此，上述因素共同促進了該市場的盈利發展。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 胜肽和寡核苷酸CDMO市場：變數、趨勢和範圍

  • 市場體系展望
  • 胜肽和寡核苷酸CDMO市場動態
  • 技術格局
  • 定價模式分析
  • 關稅影響分析
  • 供應鏈分析
  • 市場分析工具

第4章：胜肽和寡核苷酸CDMO市場：按產品分類的估算和趨勢分析

  • 細分儀表板
  • 全球胜肽和寡核苷酸CDMO市場按產品分類的變化分析
  • 全球胜肽及寡核苷酸CDMO市場規模及趨勢分析（依產品分類，2021-2033年）
  • 胜肽
  • 寡核苷酸

5. 胜肽和寡核苷酸CDMO市場：按服務類型分類的估算和趨勢分析

  • 細分儀表板
  • 全球胜肽和寡核苷酸CDMO市場按服務類型分類的變化分析
  • 全球胜肽及寡核苷酸CDMO市場規模及趨勢分析（按服務分類），2021-2033年
  • 合約開發
  • 契約製造

6. 胜肽和寡核苷酸CDMO市場：按最終用途分類的估算和趨勢分析

  • 細分儀表板
  • 全球胜肽和寡核苷酸CDMO市場按最終用途分類的變化分析
  • 全球胜肽與寡核苷酸CDMO市場規模及趨勢分析（依最終用途分類），2021-2033年
  • 製藥公司
  • 生物製藥公司
  • 其他

7. 胜肽和寡核苷酸CDMO市場：按產品、服務和最終用途分類的區域估算和趨勢分析

  • 區域市場概覽
  • 全球區域市場概覽
  • 市場規模、預測趨勢分析（2021-2033）：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 阿曼
    • 卡達

第8章 競爭情勢

  • 公司分類
    • 市場領導者
    • 新興企業
  • 胜肽和寡核苷酸CDMO市場佔有率分析，2024年
  • 公司簡介
    • PolyPeptide Group
    • STA Pharmaceutical Co. Ltd.
    • Bachem
    • Creative Peptides
    • Aurigene Pharmaceutical Services Ltd.
    • Merck KGaA
    • EUROAPI
    • Curia Global, Inc.
    • CordenPharma
    • Sylentis, SA
Product Code: GVR-4-68040-182-4

Peptide and Oligonucleotide CDMO Market Summary

The global peptide and oligonucleotide CDMO market size was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033, growing at a CAGR of 12.75% from 2025 to 2033. The market is driven due to increasing demand for complex and targeted therapeutics, growing investment in biologics and nucleic acid-based drug development, rising outsourcing trends among pharmaceutical and biopharmaceutical companies, and advancements in synthesis and delivery technologies for peptides and oligonucleotides.

In addition, oligonucleotides and peptides have shown potential in treating a wide range of ailments, including metabolic disorders, cancer, and genetic diseases. Innovations in peptide synthesis, synthetic chemistry, and oligonucleotide manufacturing have made it easier to produce and design complex molecules. This has substantially increased the applications of peptides and oligonucleotides in therapeutic usage and thus boosted the demand for contract development and manufacturing organizations (CDMOs) with specialized proficiency in these areas.

Furthermore, the rising trend toward personalized medicine has driven the need for customized peptide and oligonucleotide therapies, thereby supporting the demand for CDMOs that are vital in the production and development of these personalized treatment therapies. Moreover, regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have diligently worked on establishing guidelines for the manufacturing and development of oligonucleotides and peptides. Hence, the aforementioned factors are responsible for the lucrative growth of the market.

Global Peptide And Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peptide and oligonucleotide CDMO market report based on product, service, end use, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Peptides
  • Oligonucleotides
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Contract Development
  • Contract Manufacturing
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Norway
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Landscape Insights

Chapter 3. Peptide and Oligonucleotide CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Peptide and Oligonucleotide CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunities
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Tariff Impact Analysis
  • 3.6. Supply Chain Analysis
  • 3.7. Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Peptide and Oligonucleotide CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Peptide and Oligonucleotide CDMO Market Product Movement Analysis
  • 4.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Peptides
    • 4.4.1. Peptides Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Oligonucleotides
    • 4.5.1. Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Peptide and Oligonucleotide CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Peptide and Oligonucleotide CDMO Market Service Movement Analysis
  • 5.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
  • 5.4. Contract Development
    • 5.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Peptide and Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Peptide and Oligonucleotide CDMO Market End Use Movement Analysis
  • 6.3. Global Peptide and Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Biopharmaceutical Companies
    • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Peptide and Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.6. Oman
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.7. Qatar
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Peptide and Oligonucleotide CDMO Market Share Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. PolyPeptide Group
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product/Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. STA Pharmaceutical Co. Ltd.
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product/Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Bachem
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product/Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Creative Peptides
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product/Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Aurigene Pharmaceutical Services Ltd.
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product/Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Merck KGaA
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product/Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. EUROAPI
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product/Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Curia Global, Inc.
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product/Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. CordenPharma
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product/Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Sylentis, S.A.
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product/Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 4 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 5 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 6 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 7 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 8 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 9 U.S. Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 10 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 11 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 12 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 13 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 14 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 15 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 16 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 17 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 18 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 19 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 20 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 21 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 22 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 23 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 24 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 25 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 26 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 28 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 29 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 30 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 31 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 32 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 33 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 34 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 35 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 36 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 37 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 38 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 39 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 40 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 41 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 42 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 47 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 48 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 49 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 50 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 51 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 52 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 53 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 54 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 55 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 56 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 57 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 58 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 59 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 60 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 61 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 62 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 63 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 64 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 65 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 66 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 67 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 68 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 69 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 70 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 71 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 72 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 73 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 74 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 75 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 76 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 77 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 78 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 79 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 80 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 81 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 85 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 86 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 87 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 88 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 91 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 92 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 93 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
  • Table 94 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
  • Table 95 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 96 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Peptide and Oligonucleotide CDMO Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Commodity Flow Analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD Model Sizing & Forecasting
  • Fig. 10 Bottom-up Approach
  • Fig. 11 Market Snapshot
  • Fig. 12 Segment Snapshot
  • Fig. 13 Segment Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Competitive Landscape Snapshot
  • Fig. 16 Parent Market Outlook, 2024 (USD Million)
  • Fig. 17 Ancillary Market Outlook, 2024 (USD Million)
  • Fig. 18 Peptide and Oligonucleotide CDMO Market Dynamics
  • Fig. 19 Porter's Five Forces Analysis
  • Fig. 20 PESTEL by SWOT Analysis
  • Fig. 21 Peptide and Oligonucleotide CDMO Market Product Outlook: Segment Dashboard
  • Fig. 22 Peptide and Oligonucleotide CDMO Market, by Product Segment: Market Share, 2025 & 2033
  • Fig. 23 Peptides Market Estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Peptide and Oligonucleotide CDMO Market Service outlook: Segment dashboard
  • Fig. 26 Peptide and Oligonucleotide CDMO Market, by Service Segment: Market Share, 2025 & 2033
  • Fig. 27 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Peptide and Oligonucleotide CDMO Market End Use Outlook: Segment Dashboard
  • Fig. 30 Peptide and Oligonucleotide CDMO Market, by End Use Segment: Market Share, 2025 & 2033
  • Fig. 31 Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Regional marketplace: Key Takeaways
  • Fig. 35 North America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 U S Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 Canada Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Europe Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 UK Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 France Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Italy Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Spain Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Denmark Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Sweden Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Australia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 South Korea Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Thailand Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Brazil Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Argentina Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 MEA Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Africa Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Saudi Arabia Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Kuwait Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Oman Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Qatar Peptide and Oligonucleotide CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Market Participant Categorization
  • Fig. 91 Heat Map Analysis